Skip to main content

Table 1 Baseline Characteristics

From: Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Characteristic All patients (n = 25)
Age, year (range) 49 (30–72)
Gender: male, no. (%) 11 (44)
Race  
 Caucasian, no. (%) 22 (88)
 Asian, no. (%) 1 (4)
 Black, no. (%) 0 (0)
 Latino/Hispanic, no. (%) 1 (4)
 Other, no. (%) 1 (4)
Diagnosis  
 Glioblastoma, no. (%) 13 (52)
 Anaplastic astrocytoma, no. (%) 7 (28)
 Anaplastic oligodendroglioma, no. (%) 2 (8)
 Unspecified high grade glioma, no. (%) 2 (8)
 Gliosarcoma, no. (%) 1 (4)
Performance status, KPS (range) 80 (50–100)
Number of prior therapies, median (range) 4 (1–9)
Previously received bevacizumab, no. (%) 19 (76)
MGMT status  
 Methylated, no. (%) 4 (16)
 Unmethylated, no. (%) 12 (48)
 Unknown, no. (%) 9 (36)
IDH1 Status  
 IDH1 Mutated, no. (%) 10 (40)
 IDH1 Wild Type, no. (%) 9 (36)
 Unknown, no. (%) 6 (24)
Number of mutations by MSK-Impact, median (range) 7 (3–58)
PD-1 inhibitor  
 Pembrolizumab, no. (%) 25 (100)
Number of doses administered, median (range) 3 (1–14)
Concomitant therapy  
 Pembrolizumab monotherapy, no. (%) 6 (24)
 Bevacizumab, no. (%) 17 (68)
 Cytotoxic chemotherapy + bevacizumab, no. (%) 2 (8)
 Receiving dexamethasone at time of first dose, no. (%) 14 (56%)